Skip to content

About Us

ASEP Medical is a result of the consolidation of two development-stage companies with common missions, founders and shared investors.

Early Diagnosis

ASEP Medical is developing a first-in-class diagnostic assay for the early and rapid diagnosis of sepsis. The technology is based on the detection of unique molecular signatures of sepsis based on the immune response rather than the presence of a specific pathogen. This novel approach represents tremendous commercial potential as sepsis is one of the most expensive conditions for hospitals to treat and current methods of diagnosis (including blood cultures) can take over 24 hours and are not fully predictive.

Early Treatment

ASEP Medical has developed a peptide technology that is to be applied as medical interventions to suppress biofilm regrowth and reduce inflammation. This novel peptide technology is intended to directly address the ineffectiveness of current treatment options.

Our Values

To continually innovate to address the global crisis of SEPSIS to improve survivability and quality of life of patients.

mission

To combine the best scientific, development, and business teams necessary to achieve the unity goal of providing the best possible healthcare to those suffering with chronic infections.

Our Vision

To become the Global Market Leader in the Diagnosis and Treatment of SEPSIS.

“The goal is to tell the physician within an hour whether or not a patient will develop sepsis — who’ll go downhill quickly and who won’t. The right patients can then be moved to the ICU immediately.”

Dr. Robert Hancock

CHIEF SCIENCE OFFICER

Management Team

Rudy A. Mazzocchi

Chairman/CEO

Rudy A. Mazzocchi has over 30 years of Senior Executive Management, Technology and Intellectual Property Development, and Financing Experience (institutional, venture, private and public) in the Med-tech, Biotech, and Biopharma industries. As a founder of over a dozen Healthcare companies, he has developed and commercialized multiple technologies ranging from diagnostics to implantable medical devices, requiring demanding clinical validation and regulatory reviews, including FDA Clearance, CE Mark, and International Regulatory Approvals.

As Chairman/Acting-CEO of AGENTIX Biopharma Corp., he concurrently serves as Co-Founder/Vice-Chairman of the BioMedX Group, Executive Chairman of MY NEXT HEALTH and Independent Director of several private and public, early and growth-stage Companies, and Senior Advisor to a variety of International Corporations seeking global expansion and/or access to U.S. public markets. Rudy previously served as Executive Chairman of Establishment Labs (NASDAQ:ESTA) and Independent Director of Greatbatch/Integer Medical (NYSE:ITGR).

He is the recipient of the Technology Leadership Award, the Businessman of the Year Award, the Ernst & Young Entrepreneur of the Year Award in Healthcare, and Global Entrepreneur of the Year Award. He has also authored more than 100 patents, three published award-winning novels and a top-selling business book on Entrepreneurism.

Dr. Fadia Saad

Chief Business Development Officer / Director

Dr. Saad has an extensive track record in strategic planning and implementing significant projects for global companies, an ability to define goals and delivering results. Her strong skills in analysis of all aspects of business opportunities and synthesis into solid business cases set the basis for business development processes at Aspreva Pharmaceuticals. As Head of Business Development, she produced licensing strategies and led teams carrying the analysis of licensing opportunities. She oversaw and directed all Business Development projects, and assigned resources within the established budget requirements. As well, she managed operations of  experienced teams in R&D, intellectual property, finance and product commercialization in evaluating opportunities, building business cases, and carrying due diligence. Fadia has led more than 15 on-site due diligences and played an integral role in negotiating a number of M&As of a cumulative value exceeding $2 Billion. She has a PhD in Microbiology from McGill University and an MBA from HEC (Hautes Etudes Commerciales), University of Montreal.

Dr. Robert ("Bob") Hancock

Chief Science Officer / Director

Dr. Hancock is a leading microbiologist in Canada and has researched and taught at the University of British Columbia for nearly 40 years. Robert Hancock OC, OBC, FRSC Founder, CEO The fundamental interest of Hancock and his laboratory is in designing new therapeutic strategies to treat infections and inflammation in the light of increasing antibiotic resistance coupled with a dearth of new antibiotic discovery. His research interests include cationic host defence peptides as novel antimicrobials, anti-biofilm agents, anti-inflammatory agents and modulators of innate immunity. He has published more than 760 papers and reviews, is a highly cited author in Microbiology and listed as the 213th most cited author in the world1 with more than 100,000 citations and an h-index of 162, and has 65 patents awarded. In recognition of his work, Dr. Hancock has received numerous awards and honours including: the Prix Galien (Highest Award for Canadian Pharmaceutical Research and Innovation), the Killam Prize (Canada Council’s prize for Health Research), Michael Smith CIHR Researcher of the Year, the ICAAC Aventis Antimicrobial Research Award (Leading award worldwide for antimicrobial research) and in 2001 he was inducted as an Officer of the Order of Canada (Canada’s second highest honour).

We've got big plans.

Don't miss another update.